Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa Study of BGT-002 Tablets in Mixed Hyperlipidemia
ChiCTR2600115928Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dyslipidemia, combined dyslipidaemia and metabolic dysfunction-associated steatotic liver disease (MASLD) comparing BGT-002 group with Placebo group (2 arms). Primary endpoint: LDL cholesterol at week 12. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
BGT-002
03
Conditions
dyslipidemiacombined dyslipidaemiametabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ChiCTR2600115928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600115928.